Louise Rosenmayr-Templeton

Chief Technology Officer at Inthelia Therapeutics
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Berndorf, Lower Austria, Austria, AT
Languages
  • Fluent German speaker - Österreichische Sprachdiplom Deutsch Oberstufe C1 -
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Experience

  • Inthelia Therapeutics
    • Ireland
    • Biotechnology Research
    • 1 - 100 Employee
    • Chief Technology Officer
      • 2022 - Present

  • Tower Pharma Consulting
    • Bellakreuzstrasse 21, 2560 Berndorf, Austria
    • Founder
      • Sep 2002 - Present

      Tower Pharma Consulting is a boutique consultancy that specialises in supporting pharmaceutical product development and drug delivery. It provides a variety of scientific, technical and project management services to pharmaceutical/biotech companies and government agencies. The consultancy's key strengths lie in the following areas: 1. CMC expertise & problem-solving 2. Technology evaluation & benchmarking 3. Development of formulation strategies 4. Service provider identification & evaluation 5. Management of outsourced projects Show less

  • Boehringer Ingelheim
    • Vienna, Austria
    • Project Manager, Biotech Business Support
      • 2001 - 2002

  • Elan Corporation
    • Dublin, Ireland
    • Section Head/Technology Project Leader
      • 1997 - 2001

  • Abbott Laboratories
    • Kent, UK and North Chicago, USA
    • Team Leader/Pharmaceutical Scientist in the International Development Centre
      • 1992 - 1997

Education

  • Canterbury Christ Church University
    Diploma, Management Studies
    1995 - 1997
  • University of Nottingham
    PhD, Drug Delivery & Nanotechnology
    1987 - 1990
  • University of Strathclyde
    BSc with First Class Honours, Pharmacy
    1982 - 1986

Community

You need to have a working account to view this content. Click here to join now